title: Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
abstract: Cytokines are critical for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease. A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacological targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases. These receptors rely on Janus family of kinases (Jaks) for signal transduction. Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval. Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacological agents.
authors: Pediatric Rheumatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
authors: Apostolos
authors: A
authors: Kontzias
authors: Alexander
authors: A
authors: Kotlyar
authors: Arian
authors: A
authors: Laurence
authors: Paul
authors: P
authors: Changelian
authors: John J
authors: JJ
authors: O'Shea
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors* / Q000276:immunology; D009196:Myeloproliferative Disorders / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D018121:Receptors, Cytokine / Q000276:immunology; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D018121:Receptors, Cytokine; D053612:Janus Kinases